TG Therapeutics (TGTX) Surpasses Q2 Earnings and Revenue Estimates

分组1 - TG Therapeutics reported quarterly earnings of $0.04 per share, exceeding the Zacks Consensus Estimate of a loss of $0.04 per share, compared to a loss of $0.34 per share a year ago, representing an earnings surprise of 200% [1] - The company achieved revenues of $73.47 million for the quarter ended June 2024, surpassing the Zacks Consensus Estimate by 11.12%, and this is a significant increase from year-ago revenues of $16.07 million [2] - Over the last four quarters, TG Therapeutics has surpassed consensus EPS estimates three times and topped consensus revenue estimates four times [2] 分组2 - The stock's immediate price movement will depend on management's commentary during the earnings call and the sustainability of earnings expectations [3][4] - The current consensus EPS estimate for the coming quarter is -$0.01 on revenues of $77.12 million, and for the current fiscal year, it is -$0.01 on revenues of $297.98 million [7] - The Zacks Industry Rank for Medical - Products is currently in the bottom 42% of over 250 Zacks industries, indicating that the industry outlook can significantly impact stock performance [8]